Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Ventilation -152% Improvement Relative Risk Progression -4% Viral decay rate 66% primary Ivermectin  Krolewiecki et al.  EARLY TREATMENT  RCT Is early treatment with ivermectin beneficial for COVID-19? RCT 41 patients in Argentina (May - September 2020) Improved viral load with ivermectin (not stat. sig., p=0.086) c19ivm.org Krolewiecki et al., EClinicalMedicine, Jun 2021 Favors ivermectin Favors control

Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial

Krolewiecki et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959, NCT004381884
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19ivm.org
Proof of concept RCT with 30 ivermectin patients and 15 control patients, showing a concentration dependent antiviral activity, but no significant difference in clinical outcomes. There was no significant difference in viral load reduction between groups overall, but a significant difference was found in patients with higher median plasma ivermectin levels (72% vs. 42%, p=0.004). Mean ivermectin plasma concentration levels correlated with viral decay rate (r=0.47, p=0.02). The change in viral load is provided for the <160ng/mL and >160ng/mL groups, but not the overall treatment group. The corrigendum provides individual viral decay rates for computing the overall treatment group viral decay rate. Authors published a corrigendum: sciencedirect.com.
This is the 27th of 50 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 57th of 103 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of mechanical ventilation, 151.9% higher, RR 2.52, p = 1.00, treatment 1 of 27 (3.7%), control 0 of 14 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of progression, 3.7% higher, RR 1.04, p = 1.00, treatment 2 of 27 (7.4%), control 1 of 14 (7.1%).
viral decay rate, RR 0.34, p = 0.09, treatment 20, control 14, relative mean viral decay rate (corrigendum table 2, all treatment patients vs. all control patients), primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Krolewiecki et al., 18 Jun 2021, Randomized Controlled Trial, Argentina, peer-reviewed, 23 authors, study period 18 May, 2020 - 9 September, 2020, average treatment delay 3.5 days, dosage 600μg/kg days 1-5, trial NCT004381884 (history).
This PaperIvermectinAll
Abstract: EClinicalMedicine 37 (2021) 100959 Contents lists available at ScienceDirect EClinicalMedicine journal homepage: https://www.journals.elsevier.com/eclinicalmedicine Research paper Antiviral effect of high-dose ivermectin in adults with COVID-19: A proofof-concept randomized trial n Lifschitzb, Matías Moragasc, Marina Travaciod, Alejandro Krolewieckia,*, Adria e n Solarig, Marcelo A. Tinellih, Rube n O. Ciminoa, Ricardo Valentini , Daniel F. Alonsof, Rube b  ndezc, , Pedro E. Fleitasa, Laura Ceballosb, Marcelo Golembac, Florencia Ferna Luis Alvarez e g e i s Baeck , Javier Farina , ndez de Oliveira , German Astudillo , Ine Diego Ferna Georgina A. Cardamaf, Andrea Manganoc, Eduardo Spitzerh,1, Silvia Goldj,1, Carlos Lanusseb,1 a n, Universidad Nacional de Salta, Alvarado 751 (4530), Ora n, Instituto de Investigaciones de Enfermedades Tropicales (IIET-CONICET), Sede Regional Ora Argentina b Laboratorio de Farmacología, CONICET-CICPBA-UNCPBA, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Cenn Veterinaria de Tandil (CIVETAN), Tandil, Argentina tro de Investigacio c Unidad de Virología y Epidemiología Molecular, Hospital de Pediatría ''Prof. Dr. Juan P. Garrahan''-CONICET, Ciudad de Buenos Aires, Argentina d  nica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina Catedra de Química General e Inorga e n Medica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina Departamento de Medicina, Centro de Educacio f gicos, Departamento de Ciencia y Tecnología, Universidad Nacional Centro de Oncología Molecular y Traslacional (COMTra) y Plataforma de Servicios Biotecnolo de Quilmes, Buenos Aires, Argentina g ~ iz, Buenos Aires, Argentina Hospital Francisco J. Mun h Laboratorio Elea/Phoenix, Los Polvorines, Argentina i ~ uelas, Argentina Servicio de Infectología, Hospital Cuenca Alta, Can j n Mundo Sano, Buenos Aires, Argentina Fundacio A R T I C L E I N F O Article History: Received 22 February 2021 Revised 17 May 2021 Accepted 25 May 2021 Available online 18 June 2021 A B S T R A C T Background: There are limited antiviral options for the treatment of patients with COVID-19. Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary spectrum, has shown potent activity against SARSCoV-2 in vitro. This study aimed at assessing the antiviral effect of IVM on viral load of respiratory secretions and its relationship with drug concentrations in plasma. Methods: Proof-of-concept, pilot, randomized, controlled, outcome-assessor blinded trial to evaluate antiviral activity of high-dose IVM in 45 COVID-19 hospitalized patients randomized in a 2:1 ratio to standard of care plus oral IVM at 0¢6 mg/kg/day for 5 days versus standard of care in 4 hospitals in Argentina. Eligible patients were adults with RT-PCR confirmed SARS-CoV-2 infection within 5 days of symptoms onset. The primary endpoint was the difference in viral load in respiratory secretions between baseline and day-5, by quantitative RT-PCR. Concentrations of IVM in plasma were measured. Study registered at ClinicalTrials.gov: NCT04381884. Findings: 45 participants were recruited (30 to IVM and 15 controls) between May 18 and September 9, 2020. There was no difference in viral load reduction between groups but a significant difference was found in patients with higher median plasma IVM levels (72% IQR 5977) versus untreated controls (42% IQR 3173) (p = 0¢004). Mean..
{ 'DOI': '10.1016/j.eclinm.2021.100959', 'ISSN': ['2589-5370'], 'URL': 'http://dx.doi.org/10.1016/j.eclinm.2021.100959', 'alternative-id': ['S258953702100239X'], 'article-number': '100959', 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: A ' 'proof-of-concept randomized trial'}, {'label': 'Journal Title', 'name': 'journaltitle', 'value': 'eClinicalMedicine'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/j.eclinm.2021.100959'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2021 The Author(s). Published by Elsevier Ltd.'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-9054-1211', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Krolewiecki', 'given': 'Alejandro', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0001-7605-9744', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Lifschitz', 'given': 'Adrián', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-6897-5950', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Moragas', 'given': 'Matías', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Travacio', 'given': 'Marina', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Valentini', 'given': 'Ricardo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Alonso', 'given': 'Daniel F.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Solari', 'given': 'Rubén', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Tinelli', 'given': 'Marcelo A.', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-4253-9077', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Cimino', 'given': 'Rubén O.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Álvarez', 'given': 'Luis', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fleitas', 'given': 'Pedro E.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ceballos', 'given': 'Laura', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Golemba', 'given': 'Marcelo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fernández', 'given': 'Florencia', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Fernández de Oliveira', 'given': 'Diego', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Astudillo', 'given': 'German', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Baeck', 'given': 'Inés', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Farina', 'given': 'Javier', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-4751-5485', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Cardama', 'given': 'Georgina A.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mangano', 'given': 'Andrea', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Spitzer', 'given': 'Eduardo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Gold', 'given': 'Silvia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lanusse', 'given': 'Carlos', 'sequence': 'additional'}], 'container-title': 'eClinicalMedicine', 'container-title-short': 'eClinicalMedicine', 'content-domain': { 'crossmark-restriction': True, 'domain': ['thelancet.com', 'elsevier.com', 'sciencedirect.com']}, 'created': {'date-parts': [[2021, 6, 18]], 'date-time': '2021-06-18T03:31:21Z', 'timestamp': 1623987081000}, 'deposited': { 'date-parts': [[2022, 12, 14]], 'date-time': '2022-12-14T08:14:07Z', 'timestamp': 1671005647000}, 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T20:30:05Z', 'timestamp': 1712608205867}, 'is-referenced-by-count': 63, 'issued': {'date-parts': [[2021, 7]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 7, 1]], 'date-time': '2021-07-01T00:00:00Z', 'timestamp': 1625097600000}}, { 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 5, 26]], 'date-time': '2021-05-26T00:00:00Z', 'timestamp': 1621987200000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S258953702100239X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S258953702100239X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': '100959', 'prefix': '10.1016', 'published': {'date-parts': [[2021, 7]]}, 'published-print': {'date-parts': [[2021, 7]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'key': '10.1016/j.eclinm.2021.100959_bib0001', 'series-title': 'COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) ' 'treatment guidelines', 'year': '2020'}, { 'article-title': 'World Health Organization. Summary of global update on implementation ' 'of preventive chemotherapy against neglected tropical diseases in 2019', 'first-page': '469', 'issue': '95', 'journal-title': 'Wkly Epiemiol Rec', 'key': '10.1016/j.eclinm.2021.100959_bib0002', 'volume': '39', 'year': '2020'}, { 'DOI': '10.3390/cells9092100', 'article-title': 'Ivermectin as a broad-spectrum host-directed antiviral: the real deal?', 'author': 'Jans', 'doi-asserted-by': 'crossref', 'first-page': '2100', 'issue': '9', 'journal-title': 'Cells', 'key': '10.1016/j.eclinm.2021.100959_bib0003', 'volume': '9', 'year': '2020'}, { 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'author': 'Caly', 'doi-asserted-by': 'crossref', 'journal-title': 'Antivir Res', 'key': '10.1016/j.eclinm.2021.100959_bib0004', 'volume': '178', 'year': '2020'}, { 'DOI': '10.3389/fphar.2021.625678', 'article-title': 'Modeling of SARS-CoV-2 treatment effects for informed drug repurposing', 'author': 'Kern', 'doi-asserted-by': 'crossref', 'journal-title': 'Front Pharmacol', 'key': '10.1016/j.eclinm.2021.100959_bib0005', 'volume': '12', 'year': '2021'}, { 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of Ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19: a randomized clinical trial', 'author': 'López-Medina', 'doi-asserted-by': 'crossref', 'journal-title': 'JAMA', 'key': '10.1016/j.eclinm.2021.100959_bib0006', 'year': '2021'}, { 'DOI': '10.1186/s12936-017-1801-4', 'article-title': 'Ivermectin to reduce malaria transmission I. Pharmacokinetic and ' 'pharmacodynamic considerations regarding efficacy and safety', 'author': 'Chaccour', 'doi-asserted-by': 'crossref', 'first-page': '161', 'issue': '1', 'journal-title': 'Malar J', 'key': '10.1016/j.eclinm.2021.100959_bib0007', 'volume': '16', 'year': '2017'}, { 'DOI': '10.1093/jac/dkz524', 'article-title': 'Safety of high-dose ivermectin: a systematic review and meta-analysis', 'author': 'Navarro', 'doi-asserted-by': 'crossref', 'first-page': '827', 'issue': '4', 'journal-title': 'J Antimicrob Chemother', 'key': '10.1016/j.eclinm.2021.100959_bib0008', 'volume': '75', 'year': '2020'}, { 'DOI': '10.1016/S1473-3099(18)30163-4', 'article-title': 'Safety and mosquitocidal efficacy of high-dose ivermectin when ' 'co-administered with dihydroartemisinin-piperaquine in Kenyan adults ' 'with uncomplicated malaria (IVERMAL): a randomised, double-blind, ' 'placebo-controlled trial', 'author': 'Smit', 'doi-asserted-by': 'crossref', 'first-page': '615', 'issue': '6', 'journal-title': 'Lancet Infect Dis', 'key': '10.1016/j.eclinm.2021.100959_bib0009', 'volume': '18', 'year': '2018'}, { 'DOI': '10.1177/009127002237994', 'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of ' 'ivermectin in healthy adult subjects', 'author': 'Guzzo', 'doi-asserted-by': 'crossref', 'first-page': '1122', 'issue': '10', 'journal-title': 'J Clin Pharmacol', 'key': '10.1016/j.eclinm.2021.100959_bib0010', 'volume': '42', 'year': '2002'}, { 'DOI': '10.1208/s12248-007-9000-9', 'article-title': 'The pharmacokinetics and interactions of ivermectin in humans - a mini ' 'review', 'author': 'González Canga', 'doi-asserted-by': 'crossref', 'first-page': '42', 'journal-title': 'AAPS J', 'key': '10.1016/j.eclinm.2021.100959_bib0011', 'volume': '10', 'year': '2008'}, { 'article-title': 'Efficacy and safety of albendazole and high-dose ivermectin ' 'co-administration in school-aged children infected with Trichuris ' 'trichiura in Honduras: A Randomized Controlled Trial', 'author': 'Matamoros', 'first-page': 'ciab365', 'journal-title': 'Clin Infect Dis', 'key': '10.1016/j.eclinm.2021.100959_bib0012', 'year': '2021'}, { 'DOI': '10.1016/S1473-3099(20)30424-2', 'article-title': 'RT-PCR for SARS-CoV-2:quantitative versus qualitative', 'author': 'Han', 'doi-asserted-by': 'crossref', 'first-page': '165', 'issue': '2', 'journal-title': 'Lancet Infect Dis', 'key': '10.1016/j.eclinm.2021.100959_bib0013', 'volume': '21', 'year': '2021'}, { 'DOI': '10.1128/CMR.00074-09', 'article-title': 'Validation of laboratory-developed molecular assays for infectious ' 'diseases', 'author': 'Burd', 'doi-asserted-by': 'crossref', 'first-page': '550', 'issue': '3', 'journal-title': 'Clin Microbiol Rev', 'key': '10.1016/j.eclinm.2021.100959_bib0014', 'volume': '23', 'year': '2010'}, { 'DOI': '10.1373/clinchem.2008.112797', 'article-title': 'The MIQE guidelines: minimum information for publication of ' 'quantitative real-time PCR experiments', 'author': 'Bustin', 'doi-asserted-by': 'crossref', 'first-page': '611', 'issue': '4', 'journal-title': 'Clin Chem', 'key': '10.1016/j.eclinm.2021.100959_bib0015', 'volume': '55', 'year': '2009'}, { 'DOI': '10.1016/S0304-4017(99)00175-2', 'article-title': 'Comparative distribution of ivermectin and doramectin to parasite ' 'location tissues in cattle', 'author': 'Lifschitz', 'doi-asserted-by': 'crossref', 'first-page': '327', 'issue': '4', 'journal-title': 'Vet Parasitol', 'key': '10.1016/j.eclinm.2021.100959_bib0016', 'volume': '87', 'year': '2000'}, { 'author': 'Gibaldi', 'key': '10.1016/j.eclinm.2021.100959_bib0017', 'series-title': 'Pharmacokinetics', 'year': '1982'}, { 'DOI': '10.1002/sim.4780132309', 'article-title': 'Internal pilot studies for estimating sample size', 'author': 'Birkett', 'doi-asserted-by': 'crossref', 'first-page': '2455', 'issue': '23–24', 'journal-title': 'Stat Med', 'key': '10.1016/j.eclinm.2021.100959_bib0018', 'volume': '13', 'year': '1994'}, { 'DOI': '10.1016/j.jclinepi.2012.09.002', 'article-title': 'Sample size calculations for pilot randomized trials: a confidence ' 'interval approach', 'author': 'Cocks', 'doi-asserted-by': 'crossref', 'first-page': '197', 'issue': '2', 'journal-title': 'J Clin Epidemiol', 'key': '10.1016/j.eclinm.2021.100959_bib0019', 'volume': '66', 'year': '2013'}, { 'author': 'Cohen', 'key': '10.1016/j.eclinm.2021.100959_bib0020', 'series-title': 'Statistical power analysis for the behavioral sciences', 'year': '1988'}, { 'DOI': '10.1152/ajpendo.00178.2020', 'article-title': 'COVID-19-associated SIADH\xa0: a clue in the times of pandemic!', 'author': 'Yousaf', 'doi-asserted-by': 'crossref', 'first-page': 'E882', 'issue': '6', 'journal-title': 'Am J Physiol Endocrinol Metab', 'key': '10.1016/j.eclinm.2021.100959_bib0021', 'volume': '318', 'year': '2020'}, { 'DOI': '10.4269/ajtmh.20-0271', 'article-title': 'Ivermectin and COVID-19\xa0: keeping rigor in times of urgency', 'author': 'Chaccour', 'doi-asserted-by': 'crossref', 'first-page': '1156', 'issue': '6', 'journal-title': 'Am J Trop Med Hyg', 'key': '10.1016/j.eclinm.2021.100959_bib0022', 'volume': '102', 'year': '2020'}, { 'DOI': '10.1016/j.xphs.2021.01.017', 'article-title': 'Safety and pharmacokinetic assessments of a novel ivermectin nasal ' 'spray formulation in a pig model', 'author': 'Errecalde', 'doi-asserted-by': 'crossref', 'journal-title': 'J Pharm Sci', 'key': '10.1016/j.eclinm.2021.100959_bib0023', 'year': '2021'}, { 'DOI': '10.1016/j.xphs.2020.08.024', 'article-title': 'Development of a minimal physiologically-based pharmacokinetic model to ' 'simulate lung exposure in humans following oral administration of ' 'ivermectin for COVID-19 drug repurposing', 'author': 'Jermain', 'doi-asserted-by': 'crossref', 'first-page': '3574', 'issue': '12', 'journal-title': 'J Pharm Sci', 'key': '10.1016/j.eclinm.2021.100959_bib0024', 'volume': '109', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)31022-9', 'article-title': 'Remdesivir in adults with severe COVID-19: a randomised, double-blind, ' 'placebo-controlled, multicentre trial', 'author': 'Wang', 'doi-asserted-by': 'crossref', 'first-page': '1569', 'issue': '10236', 'journal-title': 'Lancet', 'key': '10.1016/j.eclinm.2021.100959_bib0025', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1016/j.eclinm.2020.100720', 'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms ' 'and humoral response in patients with non-severe COVID-19: a pilot, ' 'double-blind, placebo-controlled, randomized clinical trial', 'author': 'Chaccour', 'doi-asserted-by': 'crossref', 'journal-title': 'EClinicalMedicine', 'key': '10.1016/j.eclinm.2021.100959_bib0026', 'volume': '32', 'year': '2021'}, { 'DOI': '10.1371/journal.pntd.0006020', 'article-title': 'Safety and pharmacokinetic profile of fixed-dose ivermectin with an ' 'innovative 18mg tablet in healthy adult volunteers', 'author': 'Muñoz', 'doi-asserted-by': 'crossref', 'issue': '1', 'journal-title': 'PLoS Negl Trop Dis', 'key': '10.1016/j.eclinm.2021.100959_bib0027', 'volume': '12', 'year': '2018'}, { 'article-title': 'Interaction of macrocyclic lactones with P-glycoprotein\xa0: ' 'structure–affinity relationship', 'author': 'Lespine', 'first-page': '84', 'journal-title': 'Eur J Pharm Sci', 'key': '10.1016/j.eclinm.2021.100959_bib0028', 'volume': '0', 'year': '2006'}, { 'DOI': '10.1111/j.1365-2885.2007.00848.x', 'article-title': 'Involvement of P-glycoprotein on ivermectin kinetic behaviour in ' 'sheep\xa0: itraconazole-mediated changes on gastrointestinal ' 'disposition', 'author': 'Ballent', 'doi-asserted-by': 'crossref', 'first-page': '242', 'journal-title': 'J Vet Pharmacol Ther', 'key': '10.1016/j.eclinm.2021.100959_bib0029', 'year': '2007'}, { 'DOI': '10.1371/journal.pone.0158237', 'article-title': 'How can viral dynamics models inform endpoint measures in clinical ' 'trials of therapies for acute viral infections?', 'author': 'Vegvari', 'doi-asserted-by': 'crossref', 'issue': '7', 'journal-title': 'PLoS ONE', 'key': '10.1016/j.eclinm.2021.100959_bib0030', 'volume': '11', 'year': '2016'}, { 'DOI': '10.1371/journal.pone.0156622', 'article-title': 'Using clinical trial simulators to analyse the sources of variance in ' 'clinical trials of novel therapies for acute viral infections', 'author': 'Vegvari', 'doi-asserted-by': 'crossref', 'issue': '6', 'journal-title': 'PLoS ONE', 'key': '10.1016/j.eclinm.2021.100959_bib0031', 'volume': '11', 'year': '2016'}, { 'DOI': '10.1056/NEJMoa2015294', 'article-title': 'Interferon beta-1b and lopinavir–ritonavir for middle east respiratory ' 'syndrome', 'author': 'Arabi', 'doi-asserted-by': 'crossref', 'first-page': '1645', 'issue': '17', 'journal-title': 'N Engl J Med', 'key': '10.1016/j.eclinm.2021.100959_bib0032', 'volume': '383', 'year': '2020'}, { 'DOI': '10.1038/s41586-020-2196-x', 'article-title': 'Virological assessment of hospitalized patients with COVID-2019', 'author': 'Wölfel', 'doi-asserted-by': 'crossref', 'first-page': '465', 'issue': '7809', 'journal-title': 'Nature', 'key': '10.1016/j.eclinm.2021.100959_bib0033', 'volume': '581', 'year': '2020'}, { 'DOI': '10.1038/srep16222', 'article-title': 'Modulation of P2X4 /P2X7 / Pannexin-1 sensitivity to extracellular ATP ' 'via Ivermectin induces a non-apoptotic and inflammatory form of cancer ' 'cell death', 'author': 'Draganov', 'doi-asserted-by': 'crossref', 'first-page': '16222', 'journal-title': 'Sci Rep', 'key': '10.1016/j.eclinm.2021.100959_bib0034', 'volume': '5', 'year': '2015'}, { 'DOI': '10.1016/j.ijantimicag.2020.106125', 'article-title': 'Repurposing of host-based therapeutic agents for the treatment of ' 'coronavirus disease 2019 (COVID-19): a link between antiviral and ' 'anticancer mechanisms?', 'author': 'Alonso', 'doi-asserted-by': 'crossref', 'issue': '3', 'journal-title': 'Int J Antimicrob Agents', 'key': '10.1016/j.eclinm.2021.100959_bib0035', 'volume': '56', 'year': '2020'}], 'reference-count': 35, 'references-count': 35, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S258953702100239X'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized ' 'trial', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'volume': '37'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit